HAYWARD, Calif., Feb. 3, 2011 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic skin treatments will launch two new products at the 69th Annual Meeting of the American Academy of Dermatology (AAD) in New Orleans, Louisiana from February 4th through February 8th.
The international debut of Clear + Brilliant creates and defines an entirely new category of laser aesthetic treatments designed to meet the needs of consumers looking to take control of their aging process. Clear + Brilliant provides a new offering for physicians and other skin care providers to address evolving consumer needs and expand their patient base. In-depth research with patients and their skin care providers revealed an unmet need in the skin care continuum that lies between over the counter or spa treatments and far-reaching laser offerings such as Fraxel. These consumers would like a more efficacious treatment than their current regimens, but as of yet they don't need the full transformative benefits of a more aggressive laser skin resurfacing procedure. They are looking for that treatment that refreshes their skin and allows them to have control over their skin's aging process.
"The Clear + Brilliant offering demonstrates Solta's continued commitment to develop new products that meet the needs of skin care professionals and their patients," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical, Inc. "It addresses a segment of the market that is not quite ready for more extensive procedures with an effective and affordable solution for more youthful looking skin. We are excited about the potential of this product to expand our patient base and generate incremental revenue for clinicians and for the Company."
Clear + Brilliant is CE marked and the company plans to submit for FDA 510K clearance this month. The company expects to begin shipping the product to customers in certain international markets in the second quarter of 2011.
Solta will also be offering the groundbreaking Fraxel 1927 nm laser in a standalone package. The 1927 nm wavelength was introduced last year as part of the Fraxel Dual platform and has quickly become the go-to wavelength for many practices around the world to address actinic keratosis, precancerous lesions on the skin, and other skin care conditions.
The Fraxel 1927 nm is authorized for sale in the U.S., Europe, and parts of Asia. The company expects to begin shipping the product to customers in March 2011.
"Clear + Brilliant and the Fraxel 1927 strengthen our product portfolio with solutions that continue to address the needs of patients and physicians with technologies that provide superior aesthetic and therapeutic benefits delivered in a simple and elegant manner. We expect that the introduction of these two new products will contribute to our growth in 2011 and beyond," concluded Mr. Fanning.
ABOUT SOLTA MEDICAL, INC.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's four premier brands: Thermage®, Fraxel®, Isolaz®, and CLARO®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the only FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated shipment dates of the newly announced products and contributions of the new products to future growth. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from the forward looking statements contained herein. Factors that might cause such a difference include the possibility that the market for the sale of these products and initiatives does not develop as expected or that difficulties arise in the production and shipment of these products arise. Further information on potential risk factors that could affect Solta Medical's business are detailed in its Form 10-Q for the quarter ended September 30, 2010. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
© 2010 Solta Medical, Inc. All rights reserved. Thermage, Fraxel, Fraxel re:store, Isolaz, Clear+Brilliant, and Solta Medical are trademarks or registered trademarks of Solta Medical, Inc. or its subsidiaries.
SOURCE Solta Medical, Inc.